One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. “About 4 years after dupilumab’s approval, we’re…
Read MoreAflibercept Won’t Help Vision in Early Diabetic Retinopathy
Intravitreal injections with aflibercept (Eylea) don’t improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk for center-involved diabetic macular edema and proliferative diabetic retinopathy, however, said Adam R. Glassman, MS,…
Read MoreStudy investigates the prevalence of eye disease in adults with Down syndrome
Drs. Dimitrios Karamichos and Melissa Petersen at The University of North Texas Health Science Center at Fort Worth, are teaming with DownSyndrome Achieves (DSA) Biobank in Ohio to find clues about Keratoconus Dystrophy. Their research will help better identify individuals…
Read More